Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification

Mimma Rizzo; Anna Caliò; Matteo Brunelli; Gaetano Pezzicoli; Carlo Ganini; Guido Martignoni; Porta Camillo

doi:10.1016/j.ctrv.2023.102558

Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification

Cancer Treat Rev. 2023 May:116:102558. doi: 10.1016/j.ctrv.2023.102558. Epub 2023 Apr 9.

Authors

Mimma Rizzo¹, Anna Caliò², Matteo Brunelli², Gaetano Pezzicoli³, Carlo Ganini³, Guido Martignoni⁴, Porta Camillo⁵

Affiliations

¹ Division of Medical Oncology, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy. Electronic address: rizzo.mimma@gmail.com.
² Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Italy.
³ Department of Interdisciplinary Medicine, School of Medicine, University of Bari "A. Moro", Bari, Italy.
⁴ Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Italy; Department of Pathology, Pederzoli Hospital, Peschiera del Garda, Verona, Italy.
⁵ Division of Medical Oncology, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy; Chair of Oncology, Interdisciplinary Department of Medicine, University of Bari "A. Moro", Bari, Italy.

PMID: 37060647
DOI: 10.1016/j.ctrv.2023.102558

Abstract

The new WHO classification of urogenital tumours published in 2022, contains significant revisions upon the previous 2016 version regarding Renal Cell Carcinoma (RCC). While the most common histotype remains almost untouched, some of the main novelties concerns papillary RCC and oncocytic neoplasms. The main change is the introduction of a new category of molecularly-defined RCC, which includes TFE3-rearranged RCC, TFEB-rearranged, and TFEB-amplified RCC, FH-deficient RCC, SDH-deficient RCC, ALK-rearranged RCC, ELOC (formerly TCEB1)-mutated RCC, SMARCB1 (INI1)-deficient RCC. In this paper we analyze the current knowledge on emerging entities and molecularly-defined RCC to assess whether the current pathological classification offers the oncologist the possibility of selecting more specific and personalized treatments, from both those currently available, as well as those that will soon be available.

Keywords: 2022 WHO RCC classification; Clinical implications; Molecular definition; Renal cell carcinoma; Targeted therapies.

Publication types

Review

MeSH terms

Carcinoma, Renal Cell* / genetics
Carcinoma, Renal Cell* / pathology
Humans
Kidney Neoplasms* / genetics
Kidney Neoplasms* / pathology
World Health Organization